Cancer marker and therapeutic target

Patent metadata

Field	Value
Publication number	US-10261099-B2
Application number	US-201514823755-A
Country	US
Kind code	B2
Filing date	Aug 11, 2015
Priority date	Sep 18, 2007
Publication date	Apr 16, 2019
Grant date	Apr 16, 2019

Abstract

Chemokine receptor CCR4 and its ligands CCL17 and CCL22 are used as markers for the identification and/or staging of cancer. The level of CCR4, CCL17 and CCL22 are found to increase during malignant tumour progression. CCR4, CCL17 and CCL22 are used as markers for the stratification of cancer patients according to their suitability for treatment with anti-cancer agents. Information of diagnostic character is provided by measuring the level of one or more of CCR4, CCL17 and CCL22 present in a patient sample. Methods of treatment of cancer patients which agents that modulate the activity of CCR4, CCL17 and CCL22. Methods of screening for agents which modulate the biological activities of CCR4, CCL17 and CCL22 provide anti-cancer agents.

First claim

The invention claimed is:

1. A method of treating a cancer patient having a tumor comprising:
administering an effective amount of an agent that inhibits CCR4 activity to a patient identified as having a tumor comprising epithelial cells expressing CCR4,
wherein the tumor is not a breast tumor.

2. The method of claim 1 , wherein the agent which inhibits CCR4 activity is a CCR4 antagonist.

3. A method of claim 1 , wherein the tumor is a cancer selected from cancer of the cervix, oesophagus, kidney, brain, ovary, prostate, stomach or pancreas.

4. The method of claim 1 , wherein the agent is an antibody that binds CCR4.

5. The method of claim 1 , wherein the agent is an antibody that binds CCL17 or CCL22.

6. The method of claim 1 , wherein the tumor is a malignant tumor.

Assignees

• Cancer Research Tech Ltd

Inventors

• Balkwill Frances
• Slettenaar Violet
• Wilson Julia
• Wang Yaohe
• Schioppa Tiziana

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• G01N33/5759

  involving compounds localised on the membrane of tumour or cancer cells · CPC title

• G01N33/575

  for cancer · CPC title

• G01N2800/52

  Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis · CPC title

• G01N33/74 Primary

  involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors} · CPC title